



Original Article

REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer



Petra Seibold^{a,1,*}, Adam Webb^{b,1}, Miguel E. Aguado-Barrera^{c,d}, David Azria^e, Celine Bourcier^e, Muriel Brengues^f, Erik Briers^g, Renée Bultijnck^h, Patricia Calvo-Crespoⁱ, Ana Carballoⁱ, Ananya Choudhury^j, Alessandro Cicchetti^k, Johannes Claßen^l, Elena Delmastro^m, Alison M. Dunningⁿ, Rebecca M. Elliott^j, Laura Fachalⁿ, Marie-Pierre Farcy-Jacquet^o, Pietro Gabriele^m, Elisabetta Garibaldi^m, Antonio Gómez-Caamaño^{d,i}, Sara Gutiérrez-Enríquez^p, Daniel S. Higginson^q, Kerstie Johnson^r, Ramón Lobato-Busto^s, Meritxell Mollà^{t,2}, Anusha Müller^a, Debbie Payne^u, Paula Peleteiroⁱ, Giselle Post^h, Tiziana Rancati^k, Tim Rattay^r, Victoria Reyes^t, Barry S. Rosenstein^v, Dirk De Ruyscher^{w,x}, Maria Carmen De Santis^y, Jörg Schäfer^z, Thomas Schnabel^{aa}, Elena Sperk^{ab}, R. Paul Symonds^r, Hilary Stobart^{ac}, Begoña Taboada-Valladaresⁱ, Christopher J. Talbot^r, Riccardo Valdagni^{k,y,ad}, Ana Vega^{c,d,ae}, Liv Veldeman^{h,af}, Tim Ward^{ag}, Christian Weißenberger^{ah}, Catharine M.L. West^{j,3}, Jenny Chang-Claude^{a,ai,3}, REQUIRE consortium⁴

^aDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; ^bDepartment of Genetics and Genome Biology, University of Leicester, UK; ^cFundación Pública Galega de Medicina Xenómica, Grupo de Medicina Xenómica (USC), Santiago de Compostela; ^dInstituto de Investigación Sanitaria de Santiago de Compostela, Spain; ^eDepartment of Radiation Oncology, Montpellier Cancer Institute, Université Montpellier, Inserm U1194; ^fInstitut de Recherche en Cancérologie de Montpellier, Montpellier Cancer Institute, Inserm U1194, France; ^gPatient advocat, Hasselt, Belgium; ^hDepartment of Human Structure and Repair, Ghent University, Belgium; ⁱDepartment of Radiation Oncology, Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; ^jTranslational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, UK; ^kProstate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ^lKlinik für Strahlentherapie, Radiologische Onkologie und Palliativmedizin, ViDia Christliche Kliniken Karlsruhe, Germany; ^mDepartment of Radiation Oncology, Candiolo Cancer Institute – FPO, IRCCS, TO, Italy; ⁿCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Research Labs, UK; ^oDepartment of Radiation Oncology, CHU Nîmes, France; ^pOncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; ^qDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA; ^rLeicester Cancer Research Centre, University of Leicester, UK; ^sDepartment of Medical Physics, Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela; ^tRadiation Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; ^uCentre for Integrated Genomic Medical Research (CIGMR), University of Manchester, UK; ^vDepartment of Radiation Oncology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA; ^wMaastricht University Medical Center, Department of Radiation Oncology (Maastricht Clinic), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands; ^xKU Leuven, Radiation Oncology, Leuven, Belgium; ^yDepartment of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ^zStrahlentherapie Speyer; ^{aa}Klinik für Strahlentherapie und Radiologische Onkologie, Klinikum der Stadt Ludwigshafen gGmbH; ^{ab}Department of Radiation Oncology, Universitätsklinikum Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; ^{ac}Independent Cancer Patients' Voice, UK; ^{ad}Department of Oncology and Haematology-Oncology, University of Milan, Italy; ^{ae}Biomedical Network on Rare Diseases (CIBERER), Spain; ^{af}Department of Radiation Oncology, Ghent University Hospital, Belgium; ^{ag}Trustee Pelvic Radiation Disease Association, NCRi CTRad Consumer, UK; ^{ah}Zentrum für Strahlentherapie Freiburg; and ^{ai}University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany

Abbreviations: B, breast cancer patients; BCCT.core, Breast Cancer Conservation Treatment.cosmetic results; BMI, body mass index; BR23, breast module of EORTC QLQ; CTCAE, common terminology criteria for adverse effects; DICOM, Digital Imaging and Communications in Medicine; DVH, dose–volume histogram; EBRT, External beam radiotherapy; EORTC, European Organisation for Research and Treatment of Cancer; GI, gastrointestinal; GPAQ, Global Physical Activity Questionnaire; GTV, gross tumour volume; GU, genito-urinary; HDR, high dose rate brachytherapy; IMRT, intensity modulated radiotherapy; L, lung cancer patients; LDR, low dose rate brachytherapy; LiH, Lithium Heparin; MD, medical doctor; MFI, Multidimensional Fatigue Inventory; QoL, quality-of-life; P, prostate cancer patients; PSA, prostate specific antigen; RILA, radiation-induced lymphocyte assay; RR, relative risk; RT, radiotherapy; SNP, single nucleotide polymorphism; TURP, transurethral resection of the prostate; VMAT, Volumetric Arc Therapy.

* Corresponding author at: German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.

E-mail address: p.seibold@dkfz-heidelberg.de (P. Seibold).

¹ Contributed equally.

² Present address: Radiation Oncology Department, Hospital Clinic of Barcelona, Spain.

³ Shared senior authorship.

⁴ Collaborating authors listed at the end of this Section (REQUIRE consortium members).

<https://doi.org/10.1016/j.radonc.2019.04.034>

0167-8140/© 2019 The Authors. Published by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

ARTICLE INFO

Article history:

Received 29 November 2018

Received in revised form 25 April 2019

Accepted 29 April 2019

Available online 27 May 2019

Keywords:

Late radiotherapy side effects

Biomarkers

Prediction models

Breast cancer

Prostate cancer

Lung cancer

ABSTRACT

Purpose: REQUIRE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data.

Methods: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated.

Results: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA ($n = 4409$) and PAXgene tubes ($n = 3039$) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥ 2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung).

Conclusion: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers.

Patient summary: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation “damage” but it is not possible at the moment to identify those who are. REQUIRE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available.

In the REQUIRE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries.

In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUIRE will also enable a better understanding of how many people suffer with radiotherapy toxicity.

© 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 138 (2019) 59–67 This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Up to half of cancer patients undergo radiotherapy [1] and irradiation of surrounding healthy tissue is unavoidable. Patients vary in sensitivity to ionising radiation with 5–10% suffering from severe long-term effects that impact on their health-related quality-of-life [2,3] and limit the potentially curative doses prescribed to the majority.

The ability to predict those patients likely to develop adverse effects could potentially enable individualised treatments, which could decrease morbidity and/or increase survival. Models including clinical/treatment data and biomarkers have been developed to try identifying radiosensitive patients, e.g. [4–6]. However, the developed models and biomarkers have failed to progress to routine clinical use due to the lack of thorough independent validation. The ability to validate findings has been hampered by the lack of cohorts available. Cohorts are often small and heterogeneous [7–10]. Use of different toxicity scoring systems and the lack of standardised data collection reduces the ability to pool data [11], which is essential for collaborative research exemplified by Radiogenomics Consortium studies [12–19].

REQUIRE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve QALTY of life in cancer survivors) was established with the aim of validating models and biomarkers that predict a cancer patient's risk of adverse effects following radiotherapy [20]. In order to address previous limitations in pooling data and validating models and biomarkers, REQUIRE carried out an international, multi-centre, prospective observational study. To reflect the real-life situation required for application of predictive models, there was no

stipulation of the radiotherapy regimens to be delivered. However, all centres collected the same data housed in a central easily accessible database: demographics, previous and present co-morbidity, treatment and dosimetric information, longitudinal standardised radiotherapy toxicity (health professional and patient reported), and quality-of-life. A centralised biobank was established to store blood samples (extracted DNA, PAXgene tubes). Genome-wide genotyping of single nucleotide polymorphisms (SNPs) was carried out and the data added to the centralised database. A radiation-induced lymphocyte apoptosis (RILA) assay was carried out on a sub-set of patients.

The comprehensive centralised database and linked biobank will be a resource for the prospective evaluation and validation of clinical predictors and models. REQUIRE will also enable a better understanding of the scale of radiotherapy toxicity in a multi-national setting. As REQUIRE is a resource for dissemination and exploitation to the radiotherapy community, the purpose of this paper is to provide a comprehensive overview and summary of the data and material available.

Study design and methods

Study design and recruitment

A multi-centre, prospective observational cohort study was designed to recruit 5300 patients with breast, lung or prostate cancer undergoing radiotherapy with curative intent. The study aim was validating predictive models and biomarkers of radiotherapy

toxicity. Eligible patients were identified in the multi-disciplinary meetings and out-patient clinics of 26 hospitals (Supplementary Table S1) in eight countries (Belgium, France, Germany, Italy, the Netherlands, Spain, UK, the USA). Adult breast and prostate cancer patients were recruited prior to radiotherapy between 04/2014 and 10/2016 and lung cancer patients until 03/2017 (Supplementary Table S2 with inclusion and exclusion criteria). Conventional and hypofractionated radiotherapy was prescribed according to local standard-of-care regimens. The patients were followed prospectively for a minimum of 12 (lung) or 24 (breast and prostate) months, with longer follow-up encouraged where possible. The primary study endpoints were change in breast appearance (breast cancer patients), rectal bleeding (prostate) at 24 months and dyspnoea/breathlessness at 12 months (lung). Toxicity evaluation beyond these time points was encouraged. Primary and secondary endpoints are summarised in Supplementary Table S3. All patients gave written informed consent. The study was approved by local ethics committees and is registered at www.controlled-trials.com ISRCTN98496463.

Data and sample collection

Patients were recruited prior to radiotherapy (baseline) and followed as previously described (Fig. 1). The following standardised

data were collected prospectively by case report forms (CRFs): demographics, co-morbidity, treatment (with comprehensive information on radiotherapy regimens and dose to organs at risk), physics, longitudinal standardised radiotherapy toxicity (CTCAE v4.0 healthcare professional and patient reported), quality-of-life, and treatment outcome (including physician reported death). Both acute (at end of radiotherapy or at 3 months) and late toxicity data at 12 and 24 months are available for all three cancer types. Patient reported outcome (PRO) data collected were: quality-of-life including fatigue (EORTC QLQ C30 [21]; BR23 [22]; MFI [23] and physical activity (GPAQ [24])). CTCAE v4.0 based questionnaires developed to collect PRO data were adapted from those published elsewhere for the male pelvis [25] and lung [26]. The patient questionnaires were translated into local languages by two native speakers, merged, back translated by native English speakers, and validated for usability in ten patients per country.

DICOM and DVH files were collected for central storage using a standardised operating procedure (SOP). For the breast cancer patients, breast photos were taken using a SOP before radiotherapy and at the 24-month time point, and scored using BCCT.core software [27] according to a SOP, with 5% of photographs re-scored for quality assurance. A SOP was also produced for collecting blood samples. All patients donated at least two blood samples prior to




Fig. 1. Study Schema. Breast (B), prostate (P) and lung (L) cancer patients were recruited prior to radiotherapy and blood samples taken pre-radiotherapy (baseline). Toxicity was assessed prospectively by healthcare professionals (CTCAE v4.0, common terminology criteria for adverse effects) and patients (patient reported outcomes, PRO) at the end of radiotherapy (B, P), 3 and 6 months (L), 12 months and 24 months. Data collected included comprehensive cancer treatment data including radiotherapy physics data (DICOMs: Digital Imaging and Communications in Medicine, DVHs: dose-volume histograms), comorbid and other patient-related information. Quality-of-life (QoL) was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ C30 and the breast specific module BR23 (breast cancer patients only), the Multidimensional Fatigue Inventory (MFI) and the Global Physical Activity Questionnaire (GPAQ). For breast cancer patients, photos of the breasts were taken at baseline and 24 months. BCCT.core: (Breast Cancer Conservation Treatment, cosmetic results).

the start of radiotherapy: an EDTA sample for SNP genotyping plus a PAXgene (RNA) and/or a Lithium Heparin (LiH) sample. Blood samples were dispatched according to a SOP under temperature-controlled conditions to the CIGMR Biobank in Manchester, UK, where extracted DNA from blood and PAXgene samples for future RNA analysis are stored. A subset of patients from France, Germany and the UK gave LiH blood samples for prospective radiation-induced lymphocyte apoptosis (RILA) assays using an established method [7] and standardization across laboratories [28]. Genotyping data were generated using the Illumina Infinium OncoArray-500K beadchip. Following standard quality control procedures [29], genotype data were imputed using the 1000 Genomes Project (version 3) as a reference panel. The REQUITE CRFs, questionnaires and SOPs are available on request via www.requite.eu.

Data management and quality control

Each patient was assigned a unique study identifier, which links sample, health and genetic data. The ID includes a check digit to minimise errors. Data were uploaded by each recruitment site to a secure, online centralised database system (OpenClinica (<https://openclinica.com>), LimeSurvey (<https://limesurvey.org>) and a bespoke 'Manager' application based on Drupal 7 (<https://drupal.org>)) with personal logins. Quality assurance and control procedures involved site initiation visits prior to the start of the study, monitoring visits during the study, transcribing error checks, source data verification and plausibility checks including a query system. Blood and DNA samples were 2D labelled. The study is overseen by a Steering Committee that includes a Patient Advisory Board.

Analytical considerations and statistical analysis

It was initially estimated that 2-year toxicity data would be available for 75% of enrolled patients, i.e. 1575 of the original target of 2100 breast or prostate cancer patients. Based on effect sizes observed for genetic associations with radiation toxicity (e.g. [17]), a power calculation for the genetic assay showed that 1575 breast or prostate cancer patients has 80% power to detect a relative risk (RR) of >1.56 for grade ≥ 2 toxicity ($\alpha = 5 \times 10^{-5}$ for 1000 SNPs, allele frequency = 0.25, toxicity rate = 20%). For 825 patients with lung cancer the detectable RR would be 1.78. A Kruskal–Wallis test was used for comparisons between the three cancer types using SAS 9.4. Graphs were generated using R 3.5.1, ggplot 3.0.0 or SAS 9.4.

Results

Cohort characteristics

Within the time-period available, 4438 patients were enrolled: 2069 breast (99% of the original target), 1808 prostate (86%) and 561 lung (51%) cancer patients. Comprehensive cancer treatment data were available for 2057 breast, 1760 prostate and 530 lung cancer patients. The baseline characteristics and treatment information are summarised for each cancer type in Tables 1–3. Patients were aged between 23 and 91 years. The breast cancer patients were younger (median 58 years) at enrolment than the prostate (70 years) and lung (69 years) cancer patients. Most patients ($>94\%$) identified as being of European ancestry (data not shown). As expected, there were significantly more lung cancer patients who were current smokers at the time of diagnosis (43%) compared with breast (18%) and prostate (14%) patients ($p < 0.001$). Patients with lung (17%) and prostate (13%) cancer were also more likely than breast patients (6%) to have diabetes ($p = 0.049$).

The age distribution did not vary substantially by country, but per-centre analyses highlight some heterogeneity in patients and treatments across centres/countries that might pose a challenge when attempting to validate predictive models and biomarkers. For example, cancer patients tended to have a higher BMI in Spain and the UK than in the other countries (Supplementary Fig. S1a), and the proportion of *in situ* breast tumours ranged from $<10\%$ (Italy, Spain, UK) to 25% in the US centre. About one third of the breast cancer patients received adjuvant or neoadjuvant chemotherapy, with rates varying from $\sim 20\%$ (France, UK, US) to $>40\%$ (Italy, Spain). Half of the breast cancer patients were treated with intensity-modulated radiotherapy (IMRT), with a lower proportion in France and no IMRT in Italy and the US. Breast cancer patients who received IMRT ranged from $<20\%$ (France, Italy, Spain, US) to $>80\%$ (Belgium, UK). Most patients received an additional boost (68%), with lower proportions in the US (40%) and UK (10%). Hypofractionation rates were highest in Belgium and UK.

For the prostate cancer patients, 27% had a prostatectomy prior to radiotherapy (Table 2). As patients with and without previous prostatectomy differ, their characteristics are reported separately. Post-prostatectomy patients were younger, reported fewer comorbidities (e.g. hypertension: $p < 0.001$), had a higher risk class and received lower radiotherapy doses than those who underwent radical radiotherapy. The proportion of patients having a prostatectomy prior to radiotherapy varied from 7% in the UK to 55% in Belgium (Supplementary Fig. S1b). In terms of their treatment, most prostate cancer patients received 74–81 Gy with 1.8–2.0 Gy per fraction (68% of the radically irradiated patients) or 66–72 Gy with 1.8–2.0 Gy per fraction (66% of the post-prostatectomy patients). About one third of the radically treated patients and 10% of the post-prostatectomy patients received hypofractionation regimens. Most patients received Rapid arc/VMAT radiotherapy, except in Spain where 3D-conformal radiotherapy and brachytherapy were used (Supplementary Fig. S1c). In the US centre, about half of patients underwent brachytherapy. The proportion receiving hormone treatment varied from 13% (Germany) to about 80% (Belgium, UK). About 26% of the patients received hypofractionation with highest rates in Belgium, the Netherlands and UK (Supplementary Fig. S1d).

For the lung cancer patients (Table 3), 9% had surgery prior to radiotherapy with the highest proportion in Spain (19%, Supplementary Fig. S1e). About half of the patients received chemotherapy, mostly applied concurrently. Radiotherapy techniques varied widely across countries with the highest IMRT rates in Belgium and the US (Supplementary Fig. S1f). Most French patients were treated with stereotactic radiotherapy. Tomotherapy was only used at the Italian site. Moderate hypofractionation rates were highest in Belgium, Italy, the Netherlands and UK (Supplementary Fig. S1g).

Baseline levels of toxicity and quality-of-life scores

The pre-radiotherapy baseline level of adverse effects for both healthcare professional rated CTCAE v4.0 scoring as well as patient reported outcomes are presented in Supplementary Figs. S2a–2d by cancer type. They highlight that across all cancers and toxicities healthcare professional graded scores are lower than patients' grades, in particular for breast pain, certain genitourinary prostate symptoms and lung toxicities. Healthcare professional rated baseline toxicity data were available for $>99.8\%$ of the patients with radiotherapy data: 2056 breast, 1758 prostate and 529 lung. PROs were filled in by 2000 breast (97.2%), 1681 prostate (95.5%) and 462 lung (87.2%) cancer patients. In general, adverse effects grade ≥ 2 evaluated by a physician were low at baseline (particularly for gastrointestinal related toxicities in prostate cancer patients) and

Table 1

Baseline characteristics of the REQUITE breast cancer patients.

Characteristics		Breast cancer patients (N = 2057)
Age at enrolment	Median (range), years	58 years (23–90)
BMI	Mean (standard deviation), kg/m ²	26.5 kg/m ² (±5.6)
Smoking status at diagnosis	Current	365 (18%)
	Former	514 (25%)
	Never	1156 (56%)
Selected comorbidities	Diabetes, antidiabetics	127 (6%)
	Heart disease	143 (7%)
	Delayed healing >3 weeks post-surgery	52 (3%)
	Post-operative haematoma	260 (13%)
	Post-operative oedema	145 (7%)
Family history of breast cancer	Post-operative infection	91 (4%)
	First degree relatives	410 (20%)
	<i>in situ</i>	252 (12%)
Tumour size (pre-radiotherapy)	T1–T2	1728 (84%)
	T3, T4	16 (<1%)
	Negative	1488 (72%)
Nodal status (pre-radiotherapy)	Positive	394 (19%)
	Infiltrating ductal	1318 (64%)
Tumour histology	Other (including lobular, <i>in situ</i> , mixed)	739 (36%)
	Oestrogen receptor positive	1667 (81%)
Additional cancer treatment	HER2 positive	1581 (10%)
	Chemotherapy	638 (31%)
Radiotherapy	Tamoxifen, aromatase inhibitors	1574 (77%)
	Anti-HER2, targeted therapy	170 (8%)
Patients without boost*	IMRT	1018 (49%)
		662 (32%)
Patients with simultaneous boost**	50–56 Gy/≤ 2.0 Gy ²	203 (31%)
	39.9–45 Gy/2.5–3.2 Gy	452 (68%)
	28.5–32.5 Gy/5.7–6.5 Gy	7 (1%)
		257 (12%)
Patients with sequential boost**	50–52 Gy/≤ 2.0 Gy + 6–15.6 Gy/0.2–0.5 Gy (partly plus 2 Gy) ³	179 (70%)
	40.05 Gy/2.67 Gy + 6.75–10.95 Gy/0.45–0.73 Gy	35 (14%)
	28.5 Gy/5.7 Gy + 4–6 Gy/0.8–1.2 Gy	43 (17%)
		1138 (55%)
Brachytherapy boost**	50 Gy/≤ 2.0 Gy + 9–20 Gy/2–3 Gy ⁴	641 (56%)
	39.6–49.5 Gy/2.25–3.6 Gy + 10–16 Gy/2.0–3.99 ⁵	380 (33%)
		117 (10%)
	50.0 Gy/2.0 Gy + 8.5–10 Gy/8.5–10 Gy	40 (34%)
	39.9–42.56/2.66 Gy + 8.5–10 Gy/5–10 Gy	77 (66%)

BMI: Body mass index. IMRT: Intensity modulated radiation therapy.

*RT regimens: Total whole breast irradiation dose (WBI)/fraction dose.

**RT regimens: Total whole breast irradiation (WBI)/fraction dose + total boost dose/fraction dose.

²Including 6 patients with WBI dose <50 Gy.³Including 24 patients with 4 Gy or 10 Gy from sequential boost in 2 Gy fractions; 1 patient with WBI dose <50 Gy.⁴Including 24 patients with WBI dose <50 Gy; 3 patients with boost dose <9 Gy or boost fraction dose >3 Gy.⁵Including 4 patients with boost dose <10 Gy; 2 patients with boost dose 18.6 Gy.

BMI: Body mass index. IMRT: intensity-modulated radiotherapy. WBI: Whole breast irradiation dose. Numbers might not add up due to missing data.

usually <10%. Notable exceptions were the high frequencies of sexual dysfunctions among prostate cancer patients (e.g. 27% erectile dysfunction) and dyspnoea in lung cancer patients (23%).

A total of 2000 breast (97.2%), 1665 prostate (94.6%) and 457 lung cancer patients (86.2%) filled in the EORTC QLQ C30 quality-of-life baseline questionnaire (Supplementary Table S4, transformed into a scale of 0–100). Supplementary Table S5 shows the differences in baseline toxicities and quality-of-life data by country.

Summary of data available

Supplementary Table S6 provides an overview of the REQUITE resource and summarises the comprehensive data and samples available at the end of the funding period (October 2018). More than 45,000 physician and over 50,000 patient forms (including quality-of-life, fatigue and physical activity) were collected. Breast photos at baseline and 24-month of over 1500 breast cancer patients were scored to assess changes in breast appearance. More than 17,000 DVHs and 12,000 DICOMs for organs at risk were uploaded. Imputed genotype data are available for >4200 REQUITE patients with European ancestry (55.2 billion genotypes). About 1300 patients also have data on the radiation-induced lymphocyte assay. A PAXgene tube was collected from >3000 patients for future RNA analysis.

As of October 2018, follow-up CTCAE v4.0 toxicity data are available for about 1700 breast (82% of recruited patients) and 1430 prostate (79%) at 24 months and for 330 lung cancer patients (59%) at 12 months. For breast, common toxicity rates with grade ≥2 at 2 years were ~5–13%, for prostate below 5% for GI toxicities, ~3–8% for GU toxicities and ~20–31% for sexual problems. Common lung toxicity rates at one year were ~4–7% and dyspnoea rates at 27%.

Discussion

REQUITE is one of the largest radiotherapy patient cohorts with standardised longitudinal data and sample collection from multiple hospitals and countries. To overcome issues of heterogeneity encountered in previous cohorts, considerable efforts were made to ensure standardisation of data collection, which include quality assurance and quality control measures. It is hoped that other studies will use the CRFs and multi-lingual CTCAE v4.0 PRO questionnaires to further improve data collection and our ability to validate models and biomarkers of radiosensitivity [20]. Although established as a resource to validate predictive models, we anticipate its use also in discovery science, e.g., in contributing data to radiogenomics studies identifying common genetic variants associated with risk of radiotherapy toxicities [13].

Table 2
Baseline characteristics of the REQUIRE prostate cancer patients.

Characteristics	Radical radiotherapy (N = 1277)	Post-prostatectomy patients (N = 483) [#]
Age at enrolment (median, range)	71 years (42–88)	66 years (46–85)
BMI (mean, standard deviation)	27.7 kg/m ² (±4.5)	27.3 kg/m ² (±3.6)
Smoking status at diagnosis		
Current	165 (13%)	84 (17%)
Former	600 (47%)	221 (46%)
Never	508 (40%)	175 (36%)
Selected comorbidities + pre-radiotherapy surgery		
Diabetes, antidiabetics	185 (14%)	51 (11%)
Hypertension, hypertensive medication	750 (59%)	237 (49%)
Use of statins, cholesterol lowering drugs	486 (38%)	163 (34%)
History of heart disease	289 (23%)	83 (17%)
Previous abdominal surgery	675 (53%)	175 (36%)
TURP	104 (8%)	10 (2%)
Family history of prostate cancer (1st degree)	220 (17%)	100 (21%)
Tumour size (pre-radiotherapy) [†]		
T1	377 (30%)	–
T2	554 (43%)	202 (42%)
T3, T4	220 (16%)	247 (51%)
Nodal status (pre-radiotherapy) [†]		
Negative	1093 (86%)	215 (45%)
Positive	59 (5%)	75 (16%)
Gleason's score		
Gleason < 7	244 (19%)	70 (14%)
Gleason 7	709 (56%)	296 (61%)
Gleason 8–10	320 (25%)	119 (24%)
Pre-diagnostic biopsy PSA (median, range)	9.6 ng/ml (0.35–300)	8.0 ng/ml (0.1–270)
≤10 ng/ml	681 (53%)	283 (59%)
10–20 ng/ml	337 (26%)	94 (19%)
>20 ng/ml	246 (19%)	53 (11%)
Risk class (National Comprehensive Cancer Network version1.2018)		
Low (T1–T2a + Gleason ≤ 6 + PSA < 10 ng/ml)	110 (9%)	<1%
Intermediate (favourable plus unfavourable) (T2b–T2c OR Gleason = 7 OR PSA 10–20)	618 (48%)	180 (37%)
High plus very high (T3–T4 OR Gleason 8–10 OR PSA > 20 ng/ml)	543 (44%)	287 (59%)
Hormonal treatment		
None	291 (23%)	248 (51%)
Yes	986 (77%)	235 (49%)
Radiotherapy		
EBRT		
3D conformal radiotherapy	187 (16%)	101 (21%)
IMRT	145 (12%)	87 (18%)
VMAT	866 (72%)	295 (61%)
Pelvic radiotherapy	363 (28%)	161 (33%)
Total EBRT dose (Gy), without brachytherapy	54.4–81.0 Gy	51.2–77.0 Gy
EBRT regimens without brachytherapy (N = 1578, 90%)		
1.6 Gy fraction dose; 59.2 Gy total dose	2 (<1%)	–
1.8–2.0 Gy fraction dose; 66–72 Gy total dose	10 (<1%)	317 (66%)
1.8–2.0 Gy fraction dose; 74–81 Gy total dose	745 (68%)	116 (24%)
2.1–2.5 Gy fraction dose; 63–77 Gy total dose	106 (10%)	20 (4%)
>2.5–3.4 Gy fraction dose; 51.2–69.25 Gy total dose	231 (21%)	30 (6%)
EBRT regimens with brachytherapy (N = 103, 6%)		
1.8–2.0 Gy fraction dose; 45–50.4 Gy [§]	24 (23%)	–
2.45–2.54 Gy fraction dose; 36.8–38.1 Gy	79 (77%)	–
Brachytherapy	182 (14%)	–
Brachytherapy alone	79 (43%)	–
HDR	8 (10%)	–
LDR	71 (90%)	–
HDR dose (Iridium; median, range)	19 Gy (19–25)	–
LDR dose (mostly iodine; median, range)	145 Gy (124–160)	–
Brachytherapy + EBRT	103 (57%)	–
HDR	84 (82%)	–
LDR	19 (18%)	–
HDR dose (Iridium, Cobalt-60; median, range)	15 Gy (13–21)	–
LDR dose (mostly palladium; median, range)	100 Gy (85–108)	–

BMI: Body mass index. EBRT: External beam radiation therapy. HDR: High dose rate. IMRT: Intensity-modulated radiation therapy. LDR: Low dose rate. PSA: Prostate specific antigen. TURP: transurethral resection of the prostate. VMAT: Volumetric Arc Therapy.

[#]salvage (prostatectomy ≥12 months prior to RT) 56% and adjuvant (prostatectomy <12 months prior to RT) 44%. [†]Clinical T/N stages for radical radiotherapy patients and pathological T/N stages for post-prostatectomy patients. [§]Including 1 patient with incomplete dosage. Data might not add up to 100% due to missing data.

We successfully showed that it is possible to collect standardised clinical data prospectively from multiple hospitals across countries, given adequate funding to perform the labour intensive work. The actual accrual of 84% of target (4438 versus 5300) was reduced due to some centres being slow to open and the constraints due to funding limited the possibility of extending the recruitment period. There was a high return rate for questionnaires, e.g. 76% for 24 months PRO data and 81% healthcare professional reported toxicity in prostate cancer patients. In comparison single centre studies in prostate cancer patients carried out up to two years following radiotherapy reported overall questionnaire

completion rates of 50% [30], 85% in ProtecT [31], and 69% in CHHiP [32]. The REQUIRE study also aimed at a low level of missing data, e.g. only 2% of the 1665 prostate cancer patients with EORTC C30 forms had ≥10% missing quality-of-life items at baseline. In a review of randomised control trials on the extent of missing quality-of-life data, 36% of the studies had >10% missing items and for 21% the level of missing data was unclear [33].

The REQUIRE baseline toxicity rates and quality-of-life scores were comparable with other studies. For example, 27% of the prostate cancer patients recruited reported grade ≥2 erectile dysfunction at baseline compared with 32% in the radiotherapy group of

Table 3
Baseline characteristics of the REQUITE lung cancer patients.

Characteristics	Lung cancer patients (N = 530)	
Sex	Female	158 (30%)
	Male	370 (70%)
Age at enrolment	Median (range), years	69 years (39–91)
BMI	Mean (standard deviation), kg/m ²	F: 25.8 (±6.2)
		M: 26.6 (±4.8)
Smoking status at diagnosis	Current	F: 65 (41%) M: 148 (40%)
	Former	F: 78 (49%) M: 212 (57%)
	Never	F: 15 (9%) M: 8 (2%)
Selected comorbidities	COPD	F: 65 (41%) M: 150 (41%)
	Tuberculosis of the lung	F: 3 (2%) M: 10 (3%)
	Diabetes, antidiabetics	F: 19 (12%) M: 69 (19%)
	Hypertension, hypertensive medication	F: 78 (49%) M: 222 (60%)
	Heart disease	F: 32 (20%) M: 129 (35%)
Family history of lung cancer	First degree relatives	94 (18%)
Tumour histology	Squamous	176 (33%)
	Adenocarcinoma	194 (37%)
	Small cell	20 (4%)
	Other, undifferentiated	51 (10%)
	Radiological diagnosis, unknown	89 (17%)
Clinical tumour size stage (pre-radiotherapy)	0	11 (2%)
	1a, 1b	180 (34%)
	2a, 2b	139 (26%)
	3 or 4	193 (36%)
Clinical nodal stage (pre-radiotherapy)	Negative	235 (44%)
	Positive	289 (55%)
Tumour stage at diagnosis	I-II	232 (44%)
	IIIa, IIIb	287 (54%)
Additional cancer treatment	Chemotherapy	271 (51%)
	– Sequential chemotherapy	62 (23%)
	– Concurrent chemotherapy	203 (75%)
	– Consolidation chemotherapy	6 (2%)
	Surgery	48 (9%)
Radiotherapy technique	3D conformal radiotherapy	161 (30%)
	ARC therapy (VMAT, RapidARC)	70 (13%)
	IMRT	140 (26%)
	Tomotherapy	12 (2%)
	Stereotactic body radiotherapy	147 (28%)
Radiotherapy regimens		
Conventional fractionation/moderate hypofractionation		383 (72%)
	1.5 Gy fraction dose, 30–42 fractions	48 (13%)
	1.8–1.99 Gy fraction dose, 25–39 fractions	31 (8%)
	2.0 Gy fraction dose, 21–40 fractions	179 (47%)
	>2.0–3.0 Gy fraction dose, 20–33 fractions ^{#1}	109 (28%)
	4.0–5.0 Gy fraction dose, 12–24 fractions ^{#2}	16 (4%)
SABR		147 (28%)
	3 fractions à 18–20 Gy, total of 45–60 Gy	30 (20%)
	4 fractions à 8.75–15 Gy, total of 35–60 Gy	64 (44%)
	5 fractions à 10–15.27 Gy, total of 50–76.39 Gy	30 (20%)
	8 fractions à 7.5–9.18 Gy, total of 60–73.44 Gy	23 (16%)

BMI: Body mass index. COPD: Chronic obstructive pulmonary disease. F: Female. IMRT: Intensity-modulated radiation therapy. M: Male. SABR: Stereotactic ablative radiotherapy. VMAT: Volumetric Arc Therapy.

^{#1}Including 5 patients with incomplete dosage. ^{#2}Including 1 patient with incomplete dosage.

Numbers may not add up to 100% due to missing data.

the ProtecT randomised trial [34]. In lung cancer patients the rate of physician reported grade ≥ 2 dyspnoea at baseline in REQUITE was 23% compared with 15% reported elsewhere [35]. A systematic review of toxicity reporting in clinical trials identified that only 43% reported baseline data [36], highlighting the lack of reporting standards for adverse events and the need to improve the collection of baseline data. A study with 367 cancer patients [37] reported an EORTC C30 general health status/quality-of-life score of 67 at start of radiotherapy which is comparable with the REQUITE scores ranging from 61 to 74 at baseline.

We found that healthcare professional grading of adverse effects was lower than patient reported scores across three cancer types (Supplementary Figs. 2a–2d). These findings in a multi-national setting confirm a previous report [36]. Although the collection of PRO data has become established in clinical trials, challenges remain to increase understanding of clinical relevance, and to increase use in routine clinical practice [38]. Definition of treatment-induced clinically meaningful changes requires standardisation and is currently subjective [39]. The REQUITE resource will be useful for future studies developing standards that are applicable across countries.

Randomised controlled trials comparing the efficacy of different treatments provide a route for collecting multi-centre data, but are limited by restricted inclusion and exclusion criteria. Our study cohort reflects “real world” clinical radiotherapy practice across countries and will form the basis for further projects to improve prediction before treatment of those with a higher risk of long-term adverse effects after radiotherapy. The database can also be used to study various clinical questions regarding the determinants of long-term adverse effects and the longitudinal effect on quality-of-life. REQUITE will also enable a better understanding of the scale of radiotherapy toxicity in a multi-national setting and can be used to compare similarities and differences between countries. Country-specific analyses are possible. For example, fewer US lung cancer patients smoked at time of diagnosis compared to the other countries; male patients from one Spanish recruitment centre came from rural areas with lower education levels compared to other recruitment centres; and breast cancer patients in Germany were more reluctant to answer questions on sexual activity than in other countries (Supplementary Fig. S3).

The strengths of the REQUITE study are the scale of data collected, use of standardised CRFs, the centralised database and bio-

bank, the quality control methods used to maximise data quality, and the availability of genotyping data. The majority of cancer patients consented to share their data and samples with other researchers outside the REQUITE project. A data and sample access committee has been established to maximise dissemination of the resource and a cost-recovery model implemented to ensure sustainability contact. External researchers can contact requite@manchester.ac.uk for further information on how to apply for access to the data (fees apply). The www.requite.eu website provides an overview of the project and a summary of the patient characteristics. Limitations of the study include poor recruitment of lung cancer patients, follow-up currently limited to 2 years (with extension planned) and the small number of cancer types studied.

As several toxicities such as breast fibrosis may emerge many years after completion of radiotherapy, follow-up beyond two years is desirable. A longer follow-up would also allow assessment of fluctuations in symptoms over time. Funding for an extension of the follow-up to five years in some centres was secured through an ERA PERMED grant.

In summary, we successfully established an international cohort of more than 4400 cancer patients with radiotherapy and longitudinal data for future epidemiological studies. The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers.

Acknowledgements

REQUITE received funding from the European Union's Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 601826. We sincerely thank all patients that participated in the REQUITE study and all REQUITE staff involved at the following sites: Belgium: Ghent University Hospital; KU Leuven. France: ICM Montpellier, CHU Nîmes (Department of Radiation Oncology, CHU Nîmes, Nîmes, France). Germany: Praxis für Strahlentherapie an der Stadtklinik Baden-Baden; Klinikum Darmstadt GmbH; Zentrum für Strahlentherapie Freiburg; Städtisches Klinikum Karlsruhe; St. Vincentius-Kliniken gAG Karlsruhe; Klinikum der Stadt Ludwigshafen GmbH; Universitätsklinikum Mannheim: Anke Keller and Christiane Zimmermann; Strahlentherapie Speyer. The researchers at DKFZ also thank Dr Sabine Behrens and Kerstin Pieper. Italy: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Candiolo Cancer Institute – FPO, IRCCS. The Netherlands: Sylvie Canisius at Maastricht Clinics, Maastricht. Spain: Santiago: Complejo Hospitalario Universitario de Santiago. Ana Vega is supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (INT15/00070, INT16/00154, INT17/00133; PI16/00046; PI13/02030; PI10/00164), and through the Autonomous Government of Galicia (Consolidation and structuring program: IN607B); Barcelona: The authors acknowledge the Cellex Foundation for providing research facilities and equipment. S. Gutiérrez-Enríquez is supported by the Miguel Servet Program from ISCIII (CPII16/00034). UK: University Hospitals of Leicester NHS Trust, Dr Tim Rattay was funded by a National Institute of Health Research (NIHR) Doctoral Research Fellowship (DRF-2014-07-079); Manchester: Jacki Routledge at Christie NHS Foundation Trust, Manchester. Catharine West, Ananya Choudhury and Rebecca Elliott are supported by NIHR Manchester Biomedical Research Centre and Catharine West is supported by Cancer Research UK (C1094/A18504, C147/A25254); University Hospitals Birmingham NHS Foundation Trust; Derby Hospitals NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Salford

Royal NHS Trust. USA: Mount Sinai Hospital, New York; Memorial Sloan Kettering Cancer Center, New York.

Conflict of interest

D. Azria is involved in the creation of the start-up NovaGray in 2015. D. De Ruyscher: none related to the current manuscript. Outside the current manuscript: advisory board of Astra Zeneca, Bristol-Myers-Squibb, Roche/Genentech, Merck/Pfizer, Celgene, Noxxon, Molong and has received investigator initiated grants from Bristol-Myers-Squibb, Boehringer Ingelheim and Astra-Zeneca. E. Sperk: none related to the current manuscript. Outside the current manuscript: General speakers bureau Zeiss Meditec, travel support Zeiss Meditec.

The other authors have no conflict of interest to declare.

REQUITE consortium members

Yolande Lievens^{ab}, Marc van Eijkeren^{ab}, Katrien Vandecasteele^{ab}, Elhaseen Elhamin^{ab}, Piet Ost^{ab}, Valérie Fonteyne^{ab}, Martijn Swimberghe^{ab}, Pieter Deseyne^{ab}, Wilfried De Neve^{ab}, Frédéric Duprez^{ab}, Marcus Mareel^{ab}, Chris Monten^{ab}, Annick Van Greveling^a, Tom Vercauteren^{ab}, Leen Paelinck^a, Gilles Defraene^c, Rita Aerts^c, Soumia Arredouani^c, Maarten Lambrecht^c, Ben Vanneste^d, Roxana Draghici^e, Frank Giordano^f, Carsten Herskind^f, Marlon Veldwijk^f, Irmgard Helmbold^g, Ulrich Giesche^h, Petra Stegmaierⁱ, Christian Weiß^j, Thomas Blaschke^k, Burkhard Neu^l, Laura Lozza^m, Barbara Avuzzi^m, Sara Morlino^m, Claudia Sangalli^m, Marzia Franceschini^m, Belina Rodriguez-Lage^{no}, Juan Fernández-Tajes^{no}, Olivia Fuentes-Rios^{no}, Isabel Domínguez-Rios^p, Irene Fajardo-Paneque^p, Paloma Sosa-Fajardo^p, Laura Torrado-Moya^p, Mónica Ramos-Albiac^q, Alexandra Giraldo^q, Manolo Altabas^q, Bibiana Piqué-Leiva^q, David García-Relancio^q, Alejandro Seoane-Ramallo Samuel Lavers^s, Simon Wright^t, Hannah Dobbelaere^u, Donna Appleton^{tv}, Monika Kaushik^t, Frances Kenny^f, Hazem Khout^{tw}, Jaroslaw Krupa^f, Kelly V. Lambert^t, Simon Pilgrim^t, Sheila Shokuhi^t, Kalliope Valassiadou^t, Luis Aznar-Garcia^{tw}, Ion Boiangiu^{tx}, Kiran Kancherla^t, Christopher Kent^t, Kufre Sampson^t, Ahmed Osman^t, Thiagarajan Sridhar^t, Subramaniam Vasanthan^t, Corinne Faivre-Finn^{yz}, Victoria Harrop^{aa}, Manjusha Keni^{ab}, Karen Foweraker^w, Abigail Pascoe^w, Claire Esler^w, Richard Stock^{ac}, Sheryl Green^{ac}, Ava Golchin^{ac}, William Li^{ad}

^aDepartment of Radiation Oncology, Ghent University Hospital, Belgium; ^bDepartment of Human Structure and Repair, Ghent University; ^cUniversity Hospitals Leuven, Belgium; ^dMaastricht University Medical Center, Department of Radiation Oncology (Maastricht clinic), Maastricht, The Netherlands; ^eDepartment of Radiation Oncology, Montpellier Cancer Institute, Université Montpellier, Montpellier, France; ^fDepartment of Radiation Oncology, Universitätsklinikum Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim; ^gDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg; ^hKlinik für Strahlentherapie, St. Vincentius-Kliniken gAG, Karlsruhe; ⁱZentrum für Strahlentherapie Freiburg; ^jKlinikum Darmstadt, Institut für Radionkologie und Strahlentherapie, Darmstadt; ^kStrahlentherapie Baden-Baden; ^lStädt. Klinikum Karlsruhe, Germany; ^mDepartment of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁿFundación Pública Galega Medicina Xenómica, Santiago de Compostela; ^oInstituto de Investigación Sanitaria de Santiago de Compostela; ^pDepartment of Radiation Oncology, Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela;

^qRadiation Oncology Department, Vall d'Hebron University Hospital, Barcelona; ^rMedical Physics Department, Vall d'Hebron University Hospital, Barcelona, Spain; ^sLeicester Cancer Research Centre, University of Leicester; ^tUniversity Hospitals of Leicester NHS Trust; ^uDepartment of Genetics and Genome Biology, University of Leicester; ^vShrewsbury and Telford Hospital NHS Trust; ^wNottingham University Hospitals NHS Trust; ^xUniversity Hospitals of Coventry and Warwickshire NHS Trust; ^yUniversity of Manchester; ^zThe Christie NHS Foundation Trust; ^{aa}Queen Elizabeth Hospital Birmingham; ^{ab}Derby Teaching Hospitals NHS Foundation Trust, UK; ^{ac}Icahn School of Medicine at Mount Sinai; ^{ad}Queens Hospital Center, USA

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.radonc.2019.04.034>.

References

- [1] Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. *Cancer* 2005;104:1129–37.
- [2] Barker CL, Routledge JA, Farnell DJ, Swindell R, Davidson SE. The impact of radiotherapy late effects on quality of life in gynaecological cancer patients. *Br J Cancer* 2009;100:1558–65.
- [3] Schaake W, Wiegman EM, de Groot M, van der Laan HP, van der Schans CP, van den Bergh AC, et al. The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients. *Radiother Oncol* 2014;110:284–90.
- [4] Barnett GC, Kerns SL, Noble DJ, Dunning AM, West CM, Burnet NG. Incorporating genetic biomarkers into predictive models of normal tissue toxicity. *Clin Oncol (R Coll Radiol)* 2015;27:579–87.
- [5] Kerns SL, de Ruyscher D, Andreassen CN, Azria D, Barnett GC, Chang-Claude J, et al. STROGAR – strengthening the reporting of genetic association studies in radiogenomics. *Radiother Oncol* 2014;110:182–8.
- [6] Rancati T, Fiorino C, Fellin G, Vavassori V, Cagna E, Casanova Borca V, et al. Inclusion of clinical risk factors into NCTP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. *Radiother Oncol* 2011;100:124–30.
- [7] Azria D, Riou O, Castan F, Nguyen TD, Peignaux K, Lemanski C, et al. Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of breast fibrosis after radiotherapy: results of the prospective multicenter french trial. *EBioMedicine* 2015;2:1965–73.
- [8] Mbah C, Thierens H, Thas O, De Neve J, Chang-Claude J, Seibold P, et al. Pitfalls in prediction modeling for normal tissue toxicity in radiation therapy: an illustration with the individual radiation sensitivity and mammary carcinoma risk factor investigation cohorts. *Int J Radiat Oncol Biol Phys* 2016;95:1466–76.
- [9] Seibold P, Behrens S, Schmezer P, Helmbold I, Barnett G, Coles C, et al. XRCC1 polymorphism associated with late toxicity after radiation therapy in breast cancer patients. *Int J Radiat Oncol Biol Phys* 2015;92:1084–92.
- [10] Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, et al. A replicated association between polymorphisms near TNFalpha and risk for adverse reactions to radiotherapy. *Br J Cancer* 2012;107:748–53.
- [11] Deasy JO, Bentzen SM, Jackson A, Ten Haken RK, Yorke ED, Constone LS, et al. Improving normal tissue complication probability models: the need to adopt a “data-pooling” culture. *Int J Radiat Oncol Biol Phys* 2010;76:S151–4.
- [12] Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruyscher D, Cesaretti JA, et al. Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. *Radiother Oncol* 2016;121:431–9.
- [13] Kerns SL, Dorling L, Fachal L, Bentzen S, Pharoah PD, Barnes DR, et al. Meta-analysis of genome wide association studies identifies genetic markers of late toxicity following radiotherapy for prostate cancer. *EBioMedicine* 2016;10:150–63.
- [14] Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, et al. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. *Radiother Oncol* 2014;111:178–85.
- [15] Fachal L, Gomez-Caamano A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P, et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. *Nat Genet* 2014;46:891–4.
- [16] Rosenstein BS, West CM, Bentzen SM, Alsner J, Andreassen CN, Azria D, et al. Radiogenomics: radiobiology enters the era of big data and team science. *Int J Radiat Oncol Biol Phys* 2014;89:709–13.
- [17] Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. *Lancet Oncol* 2012;13:65–77.
- [18] Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, et al. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. *Radiother Oncol* 2012;105:289–95.
- [19] West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, et al. Establishment of a radiogenomics consortium. *Int J Radiat Oncol Biol Phys* 2010;76:1295–6.
- [20] West C, Azria D, Chang-Claude J, Davidson S, Lambin P, Rosenstein B, et al. The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors. *Clin Oncol (R Coll Radiol)* 2014;26:739–42.
- [21] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365–76.
- [22] Sprangers MA, Groenvold M, Arraras JL, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. *J Clin Oncol* 1996;14:2756–68.
- [23] Smets EM, Garssen B, Cull A, de Haes JC. Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. *Br J Cancer* 1996;73:241–5.
- [24] Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. *J Phys Act Health* 2009;6:790–804.
- [25] Farnell DJ, Mandall P, Anandadas C, Routledge J, Burns MP, Logue JP, et al. Development of a patient-reported questionnaire for collecting toxicity data following prostate brachytherapy. *Radiother Oncol* 2010;97:136–42.
- [26] Christodoulou M, McCloskey P, Stones N, Bayman N, Burt P, Chittalia A, et al. Investigation of a patient reported outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. *Radiother Oncol* 2014;112:244–9.
- [27] Cardoso MJ, Cardoso J, Amaral N, Azevedo I, Barreau L, Bernardo M, et al. Turning subjective into objective: the BCCT.core software for evaluation of cosmetic results in breast cancer conservative treatment. *Breast* 2007;16:456–61.
- [28] Talbot CJV, M. R.; Azria, D.; Batini, D.; Bierbaum, M.; Brengues, M.; Chang-Claude, J.; Johnson, K.; Keller, A.; Smith, S.; Sperk, E.; Symonds, R. P.; Wenz, F.; West, C.; Herskind, C.; Bourcier, C. Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity. Submitted.
- [29] Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature* 2017;551:92–4.
- [30] Choudhury A, Arthur C, Malik J, Mandall P, Taylor C, Alam N, et al. Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy. *Clin Oncol (R Coll Radiol)*. 2014;26:661–7.
- [31] Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. *N Engl J Med* 2016;375:1425–37.
- [32] Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol* 2015;16:1605–16.
- [33] Fielding S, MacLennan G, Cook JA, Ramsay CR. A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. *Trials* 2008;9:51.
- [34] Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, et al. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. *BJU Int* 2016;118:869–79.
- [35] Voets AM, Oberije C, Struijk RB, Reymen B, De Ruyc K, Thierens H, et al. No association between TGF-beta1 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients. *Radiother Oncol* 2012;105:296–8.
- [36] Gilbert A, Ziegler L, Martland M, Davidson S, Efficace F, Sebag-Montefiore D, et al. Systematic review of radiation therapy toxicity reporting in randomized controlled trials of rectal cancer: a comparison of patient-reported outcomes and clinician toxicity reporting. *Int J Radiat Oncol Biol Phys* 2015;92:555–67.
- [37] Yucel B, Akkas EA, Okur Y, Eren AA, Eren MF, Karapinar H, et al. The impact of radiotherapy on quality of life for cancer patients: a longitudinal study. *Support Care Cancer* 2014;22:2479–87.
- [38] Siddiqui F, Liu AK, Watkins-Bruner D, Movsas B. Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. *J Clin Oncol* 2014;32:2920–7.
- [39] Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T, et al. Estimating clinically significant differences in quality of life outcomes. *Qual Life Res* 2005;14:285–95.